Arena's Obesity Drug Safe for Trial
- Loading Comments...
Arena Therapeutics(ARNA Quote) said Tuesday that an independent data safety monitoring board (DSMB) gave it the green light to continue its ongoing phase III trial on obesity drug lorcaserin.
The board found no substantial evidence of heart-valve damage six months into the Bloom study. The news brightens the program's risk profile, but investors still have to bet on safety data that will be assessed at 12, 18 and 24 months.
The DSMB review evaluated heart-valve damage, the culprit behind the 1997 recall of Wyeth's(WYE Quote) fen-phen (fenfluramine/phentermine) weight-loss drug. It's an important safety checkpoint for lorcaserin, which will have to continue to pass such evaluations further into the course of Arena's Bloom study. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet